VPH2

Heart failure accounts for almost a quarter of all admissions to hospital for cardiovascular events, has a high mortality (median survival around 18 months), and places a great burden on all healthcare systems, with estimated direct costs of £905m (1350m) in the United Kingdom in 2000, 2% of total NHS expenditure.

Virtual pathological heart of the virtual physiological human (VPH2) project aims to develop a patient-specific computational modelling and simulation of the human heart to assist the cardiologist and the cardiac surgeon in defining the severity and extent of disease in patients with post-ischemic Left Ventricular Dysfunction (LVD), with or without ischemic mitral regurgitation (IMR). Specific computational methods will allow clinical decision making and planning of the optimal treatment for left ventricle-valve repair. The goal is not only to deploy a fully validated technology to partner clinical institutions, but also to develop a sustainable business model associated to it.

The associated technological aim of the project is to deliver the most advanced software application framework for the development of computer-aided medicine in cardiology and cardiac surgery available in the world, going beyond the state of the art of available models.

This goal will be achieved by integrating some of the leading Open Source software in the area of computer-aided medicine and of computational bioengineering. This framework will be used by VPH2 to realise its objectives, but also by any other future project (academic or industrial) aiming to improve or extend VPH2 objectives.

For further information, please visit:
http://www.vph2.eu

Project co-ordinator:
GMD - Gesellschaft für Medizinische Datenverarbeitung mbH

Partners:

  • Intercon Sp. Z o.o. (Poland)
  • Euro PMS ltd (United Kingdom)
  • Sorin Biomedica Cardio S.r.l. (Italy)
  • SCS S.r.l. (Italy)
  • EREYNITIKO AKADIMAIKO INSTITOUTO TECHNOLOGIAS YPOLOGISTON (Greece)
  • Westfälische Wilhelms-Universität Münster (Germany)
  • PATMOS S.r.l. (Italy)
  • Aminio AB (Sweden)
  • Ecole Polytechnique Fédérale de Lausanne (Switzerland)
  • University of Bedfordshire (United Kingdom)
  • Regione Lombardia (Italy)
  • Quality & Reliability S.A (Greece)

Timetable: from 07/2008 - to 06/2011

Total cost: € 5.180.000

EC funding: € 3.780.000

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

First Virtual DMEA to Open with a Wide R…

16 - 18 June 2020, Berlin, Germany. Under the heading 'DMEA sparks' and taking place for the first time, this year's DMEA is an entirely virtual event. From 16 to 18...

Philips Launches HealthSuite Clinical Tr…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced Clinical Trial Accelerator on Philips HealthSuite. This new tailored set of capabilities allows life science organizations to...

New AI Diagnostic can Predict COVID-19 w…

Researchers at King's College London, Massachusetts General Hospital and health science company ZOE have developed an artificial intelligence diagnostic that can predict whether someone is likely to have COVID-19 based...

Biomax Provides AI-Based Semantic Search…

The bioinformatics company Biomax, headquartered in Planegg, Germany, makesitssemantic search platform AILANI available free of charge to research institutes around the world in order to support the rapid and successful...

COVID-19 and Health Tech: Building on th…

Highland Marketing's advisory board met to discuss the health tech response to the coronavirus outbreak. In many areas, this has been hugely impressive: but there are gaps, and there will...

InsurTech Hub Munich and dmac/Digital He…

InsurTech Hub Munich (ITHM) and dmac - Medical Valley Digital Health Application Center part of the Digital Health Hub Nuremberg/Erlangen announce a new cross-industry accelerator for the second half of...

Viveo Health Offers Free Telemedicine So…

Viveo Health, a global e-Health innovator, is making its 'Virtual Office for Doctors' platform free of charge to doctors and other medical professionals worldwide in light of the surge in...

The Dedalus Group, Participated by Ardia…

The Dedalus Group, a leading European company, and one of the worldwide main ones, active in clinical healthcare information systems to support clinical professionals and organizations in order to improve...

Supercomputer Simulations Present Potent…

Several drugs approved for treating hepatitis C viral infection were identified as potential candidates against COVID-19, a new disease caused by the SARS-CoV-2 coronavirus. This is the result of research...

The COVID-19 pandemic reveals the potent…

Two new articles provide insights on the use of telehealth or virtual care in the age of COVID-19 and beyond, pointing to its value to not only prevent contagious diseases...

WiFi SPARK Works with Visionable to Conn…

Seven NHS Trusts are using technology developed by WiFi SPARK in response to an urgent request from leading NHS Trusts to find a way to connect hospital patients with their...

Digital Contact Tracing for COVID-19: An…

An article in CMAJ (Canadian Medical Association Journal) analyzes the strengths and limitations of digital contact tracing for people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to help...